Form 4 Sage Therapeutics, Inc. For: Apr 17 Filed by: STARR KEVIN P
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Sage Therapeutics (SAGE) Weakness is a Buying Opportunity - RBC
April 23, 2018 10:20 AM EDTRBC Capital analyst Brian Abrahams sees weakness in Sage Therapeutics (NASDAQ: SAGE) on Friday, related to insider selling and a deal with Biogen for IONS, as a buying opportunity.
"... we view these as non-fundamental, and Friday's detailed, in-line brexanolone data, today's on-track NDA filing,... More
